Background: Atopic dermatitis (AD) is a chronic inflammatory disease characterized by profound microbial dysbiosis, Staphylococcus aureus (S. aureus) colonization, and a compromised epidermal barrier. Current therapies often face safety and compliance limitations, necessitating proactive, steroid-sparing ecological strategies focused on barrier restoration. Methods: This pharmacological review evaluates a synergistic framework combining Lactobacillus and Saccharomyces postbiotic lysates with Perilla frutescens-derived effector vesicles. The analysis focuses on their molecular impact on skin homeostasis and structural protein synthesis. Results: In vitro evaluations indicate that Lactobacillus enhances innate immunity, while Saccharomyces-derived metabolites support the microbial ecosystem. Preliminary data demonstrate a significant impact on structural integrity, showing an 87.9% increase in elastin secretion and a 61.4% increase in Type I collagen synthesis. Furthermore, Perilla frutescens-derived vesicles modulate the JAK–STAT pathway, demonstrating a potential reduction of Interleukin-6 (IL-6) by 40% and a downregulation of CYP1A1 expression by up to 49% in cell models, thereby suggesting a capacity to mitigate oxidative stress and pruritus. Conclusions: By integrating these components into a “Triple-Action” framework, focusing on immunomodulation, structural restoration, and precision signaling, this review provides a comprehensive roadmap for promising dermo-cosmetic interventions in atopic skin management.
Badale et al. (Mon,) studied this question.